Veterinary Biologics Market Value to Surpass US$ 10 Bn Mark by 2021
Amidst the growing pressure on farmers to feed the ever-rising population in an environmentally sustainable manner, livestock production – while increasing – is still facing barriers regarding infectious and parasitic diseases. However, advancements in biotechnology and incremental innovations are promising improved diagnostics and genomics applied to develop next-gen veterinary biologics to prevent livestock diseases. As per Future Market Insights’ report, the global veterinary biologics market is estimated to grow 7% y-o-y in 2020, to attain a valuation of US$ 10.6 Bn in 2021. Moreover, massive consolidations seem to hold center stage, with key players focusing on acquisitions.
Frequently Asked Questions about Veterinary Biologics Market
Which region is expected to be at the forefront in terms of revenue in the global veterinary biologics market?
Europe is expected to be the dominant region in terms of revenue, owing to the growing trend of animal ownership in the region. However, East Asia is expected to gain significant traction regarding the sales of veterinary biologics during the forecast period.
Which product segment would be the most attractive for investments?
Vaccines emerged as the most attractive segment by product type with the highest revenue share in the veterinary biologics market. Notable growth is attributed to the use of vaccines in bulk or large batches for herd immunity in companion animals as well as livestock.
Which animal type segment would be the most prominent over the forecast period?
Livestock remains the most prominent segment, and is expected to continue to do so during the forecast period, owing to the increasing demand for processed animal origin food items.
Which distribution channel would contribute maximum revenue share during the forecast period?
Veterinary clinics offering veterinary biologics in bulk batches are expected to hold more than 1/3 of total veterinary biologics market revenue share during the forecast period.
What strategies are prominent players in the veterinary biologics market following?
Zoetis, Boehringer Ingelheim, Ceva, Elanco Animal Health, and Merck Animal Health are the top five players in the veterinary biologics market. Mergers and acquisitions, new product development, and subsequent launches are key strategies followed by these players. Veterinary biologics product manufacturers mainly rely on direct sales to gain better access to end users.
What are impediments in the veterinary biologics market growth?
Some of the prominent factors that might hamper the growth of the veterinary biologics market are gaps in epidemiological knowledge, regional variations in disease patterns, pitfalls in identifying and understanding antigen/immunogenic structures, and commodity-cycle-based nature of veterinary biologics. These factors make the market volatile and over dependent on governmental distribution channels for the supply of veterinary biologics.
Veterinary Vaccines to Capture 92% of Total Sales
Apart from humans, preventive healthcare is becoming a key component of the overall wellbeing of all animals, large and small, thereby potentially raising the demand for veterinary vaccines. Accounting for over 90% of total revenue share, the category will continue to witness higher innovation and investments. As diseases continue to evolve, an embrace of R&D on vaccines has also been underway to protect animals against new strains. Further, innovations are forthcoming for veterinary biologics such as monoclonal antibodies and immunomodulators. Approval of Zoetis’ ‘Cytopoint’ – the first monoclonal antibody for veterinary use by the European Union – has influenced manufacturers to invest in this category.
Europe to Lead the First Wave of Growth
Europe remains in the vanguard of the global veterinary biologics market, accounting for 1/3 of the revenue share. Growing number of households owing a pet and subsequent rise in demand for pet insurance in the region are key growth influencers of the market. Moreover, governments are actively taking part in improved animal health services, which have worked to the advantage of market players. High growth opportunities are also expected in Asian countries, especially in China and India, where the pet adoption rate is growing at significant pace. Furthermore, increasing incidence of foodborne and zoonotic diseases in livestock animals will contribute to the increase demand for veterinary biologics in both, East Asia and South Asia.
* This data is only a representation. Actual data may vary and will be available in report.
Strategic Collaborations and Advances in Veterinary Science – Growth Promoters
In the current scenario, the veterinary biologics market shows a high level of consolidation, with key players such as Zoetis, Boehringer Ingelheim, Ceva, Elanco Animal Health, and Merck Animal Health accounting for 2/3 of the revenue share. These players are increasingly outsourcing their innovation to startups and other collaborators with advanced expertise in the field of genomics and biotech. Moreover, the veterinary biologics market is expected to reach new heights, on account of continued investments in veterinary science and multi-disciplinary vaccinology research. Major transition in the animal health industry, in view of increased livestock production and booming sales of pet products, will further open a window of growth opportunities.
Vaccines account for 90% revenue share
Demand for monoclonal antibodies to see quantum leap
Veterinary biologics for livestock to take the lead
Surging application in equine
Adoption in veterinary clinics remains bullish
Sales through retail pharmacies pick pace
How Growth will Unfold
Demand for veterinary biologics is currently based on the increasing number of veterinary clinics in both, developed and developing countries, which account for 2/5 of the total revenue share. In order to improve their profit margins and regional presence, market stakeholders are directing the sales of their products through retail pharmacies. Significant growth in the sales of veterinary biologics through these channels can also be attributed to greater government emphasis on the unification of research in veterinary drugs and human medicine. However, an existing large gap in understanding the epidemiology pattern of animal diseases continues to represent a potential threat for market players.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
Veterinary Biologics Market Analysis 2019-2029
A recent market study published by Future Market Insights (FMI) on the veterinary biologics market includes global industry analysis for 2014-2018 and opportunity assessment for 2019-2029, and delivers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the veterinary biologics market, growth prospects are obtained with maximum precision.
Veterinary Biologics Market Taxonomy
The global veterinary biologics is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Attenuated Live Vaccines
- Conjugate Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- Toxoid Vaccines
- DNA Vaccines
- Recombinant Vaccines
- Bacterial Extracts
- Monoclonal Antibodies
- Allergenic Extracts
- Companion Animals
- Veterinary Clinics
- Veterinary Hospitals
- Veterinary Research Institutes
- Retail Pharmacies
- North America
- Latin America
- East Asia
- South Asia
- Middle East & Asia (MEA)
The report initiates with the executive summary of the veterinary biologics market, which includes a summary of key findings and statistics of the market. It also includes market size and revenue distribution of market segment of the veterinary biologics market.
Readers can find the definition and a detailed segmentation of the veterinary biologics market in this chapter, which will help them understand the basic information about the market.
This chapter explains the key trends that are expected to influence the growth of the veterinary biologics market over the forecast period. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section.
This section includes premium insights such as epidemiology of various veterinary diseases, region wise regulations for veterinary biologics.
This section explains the global market value analysis and forecast for the veterinary biologics during the forecast period. This chapter includes a detailed analysis of the historical veterinary biologics market.
This section includes premium insights such as macroeconomic factors, drivers, opportunity and restraints.
Based on product, the veterinary biologics market is segmented into vaccines, bacterial extracts, monoclonal antibody, immunomodulators and allergenic extracts. In this chapter, readers can find information about the key trends and developments in the veterinary biologics and market attractiveness analysis based on product.
This chapter provides details about the veterinary biologics market based on Animal Type, and has been classified into companion animals, livestock animals and equine animals. In this chapter, readers can understand the market attractiveness analysis based on animal Type.
This chapter provides details about the veterinary biologics market based on distribution channel, and has been classified into veterinary clinics, veterinary hospitals, veterinary research institutes and retail pharmacies. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.
This chapter explains how the veterinary biologics market will grow across various geographic regions such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA).
This chapter includes a detailed analysis of growth of the North America Veterinary Biologics market, along with a country-wise assessment that includes the U.S. and Canada. Readers can also find the pricing analysis, regional trends, and market growth based on the application and countries in North America.
This chapter provides the growth scenario of the veterinary biologics market in Latin American countries such as Argentina, Brazil, Mexico, and the Rest of Latin America. Along with this, assessment of the market across target segments has been provided.
This chapter provides the growth scenario of the veterinary biologics market in Europe in several countries such as Germany, the U.K., France, Spain, Italy, BENELUX, Russia and the Rest of Europe are included in this chapter.
This chapter provides the growth scenario of the veterinary biologics market in East Asia in several countries such as China, Japan and South Korea are included in this chapter.
This chapter highlights the growth of the veterinary biologics in South Asia by focusing on India, Thailand, Indonesia, Malaysia, rest of South Asia. This section also help readers understand the key factors that are responsible for the growth of the veterinary biologics market in South Asia.
This chapter highlights the growth of the veterinary biologics in Australia and New Zealand. This section also help readers understand the key factors that are responsible for the growth of the veterinary biologics market in Oceania.
This chapter provides information about how the veterinary biologics market will grow in major countries in the MEA region such as GCC Countries, South Africa, and the Rest of MEA, during the forecast period (2019-2029).
In this chapter, readers can find tier wise contribution of key market players along with their company market share.
In this chapter, readers can find a comprehensive list of all the prominent stakeholders in the veterinary biologics market, along with a detailed information about each company, which includes company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are Ceva, Boehringer Ingelheim, Boehringer Ingelheim, Merck Animal Health, etc.
This chapter includes a list of acronyms and assumptions that provides a base to the information and statistics included in the veterinary biologics report.
This chapter help readers understand the research methodology followed to obtain various conclusions as well as important qualitative and quantitative information about the veterinary biologics.
How the research was conducted?
- Marketing Directors
- Product Managers
- Business Development Officers
- Production Managers
- Sales Executives
- Industry Experts
- Current Market Dynamics and Challenges
- Yesteryear Trends
- Market Characteristics
- Market Performance and Growth Quadrants
- Strategic Growth Initiatives
- Near-term and Long-Term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- American Veterinary Medical Association
- American Society of Animal Science
- Company Press Releases
- Annual Reports and Investor Presentations
- Research Papers
- Government Websites and Publications
Primary Interview Splits